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Synopsis
Cbl (cobalamin) utilization as an enzyme cofactor is dependent on its efficient transit through lysosomes to the cytosol
and mitochondria. We have previously proposed that pathophysiological perturbations in lysosomal function may in-
hibit intracellular Cbl transport with consequences for down-stream metabolic pathways. In the current study, we
used both HT1080 fibroblasts and SH-SY5Y neurons to assess the impact that protease inhibitors, chloroquine
and leupeptin (N-acetyl-L-leucyl-L-leucyl-L-argininal), have on the distribution of [57Co]Cbl in lysosomes,
mitochondria and cytosol. Under standard cell culture conditions the distribution of [57Co]Cbl in both neurons and
fibroblasts was ∼5% in lysosomes, 14% in mitochondria and 81% in cytosol. Treatment of cells with either 25 μM
chloroquine or 40 μM leupeptin for 48 h significantly increased the lysosomal [57Co]Cbl levels, by 4-fold in fibroblasts
and 10-fold in neurons, and this was associated with reduced cytosolic and mitochondrial [57Co]Cbl concentrations.
Based on Western blotting of LAMP2 in fractions recovered from an OptiPrep density gradient, lysosomal Cbl trapping
was associated with an expansion of the lysosomal compartment and an increase in a subpopulation of lysosomes
with increased size and density. Moreover, the decreased mitochondrial Cbl that was associated with lysosomal
Cbl trapping was correlated with decreased incorporation of [14C] propionate into cellular proteins/macromolecules,
indicating an inhibition of Cbl-dependent Mm-CoA (methylmalonyl-coenzyme A) mutase activity. These results add
support to the idea that lysosomal dysfunction may significantly impact upon Cbl transport and utilization.
Key words: lysosome, mitochondria, neurodegeneration, subcellular-fractionation, vitamin B12.
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INTRODUCTION
Vitamin B12 [Cbl (cobalamin)] is required for erythrocyte form-
ation and DNA synthesis, and plays a critical role in the main-
tenance of neuron function [1,2]. In plasma and interstitial fluids,
Cbl is bound to TC (transcobalamin). The cellular uptake of
the TC–Cbl complex is mediated by the TCR (transcobalamin
receptor) on the cell surface. The endocytosed complex is de-
livered to the lysosome where the Cbl is released subsequent to
TC proteolysis, whereas the TCR is recycled back to the cell
surface [3]. Once Cbl is transported out of the lysosome, it is
converted to either MeCbl (methyl cobalamin) in the cytosol
or AdoCbl (adenosyl cobalamin) in the mitochondria. MeCbl is
used to transform Hcy (homocysteine) to methionine (Met) via
cytosolic MS (methionine synthase), whereas AdoCbl is required
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for the conversion of Mm-CoA (methylmalonyl-coenzyme A) to
Succ-CoA (succinyl-coenzyme A) via MMCM (mitochondrial
methylmalonyl-coenzyme A mutase). Succ-CoA then enters the
Krebs cycle, after which it is utilized in many pathways including
conversion to succinate; that may be used in protein synthesis or
in the synthesis of porphyrins. Since, extracellular propionic acid
is efficiently taken up into cells, converted to propionyl-CoA,
then converted to Mm-CoA (via the sequential actions Mm-CoA
racemase and MMCM), the incorporation of [14C]-propionic acid
into cellular macromolecules such as proteins [that are precipit-
ated by TCA (trichloroacetic acid) in vitro] is thus an established
clinical and basic research tool for evaluating the Cbl-dependent
activity of MMCM [4,5].
The importance of the role that the lysosome plays in the
delivery of Cbl to MS and MMCM has been highlighted by
the discovery of two inborn errors of Cbl metabolism referred
c© 2014 The Author(s) This is an Open Access article distributed under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/)
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to as cblF and cblJ [5–7]. These life-threatening conditions are
caused by a loss of function in either LMBD1 or ABCD4, lyso-
somal membrane proteins that normally promote Cbl efflux from
the lysosome to the cytosol [5,7]. In cblF and cblJ subjects, Cbl
accumulates in lysosomes and the levels of toxic metabolites Hcy
and MMA (methylmalonic acid) increase [5,7].
In a seminal paper describing the defective transfer of lyso-
somal Cbl to the cytosol in fibroblasts derived from a human
patient, chloroquine was also used to retard intralysosomal pro-
teolysis in control fibroblasts in order to model lysosomal Cbl
trapping [6]. Interestingly, it is known that the acidic pH of the
lysosome also influences the conversion of Cbl from the ‘base-on’
to the ‘base-off’ state, which refers to the interaction of the di-
methylbenzimidazole moiety of the Cbl molecule with the central
Co atom [8]. The Cbl base-off state is thought to be important for
subsequent interactions of Cbl with cytosolic cargo proteins. As
chloroquine inhibits lysosomal proteases by disrupting the H+
gradient across the lysosomal membrane and thereby neutraliz-
ing the normally acidic lysosomal pH [9], it is also possible that
chloroquine could at least partly inhibit Cbl intracellular transport
by blocking its conversion to the base-off state.
It is therefore clear from the cblF and cblJ inborn errors of
Cbl metabolism that transit through the intracellular lysosomal
compartment is a strict prerequisite for Cbl utilization by MS
and MMCM [3,10–12]. We have also proposed that a more gen-
eralized, pathophysiological impairment of lysosomal function
that occurs in various disease conditions, such as Alzheimer’s
disease, lysosomal storage disorders and in age-related neuronal
lipofuscinosis, may similarly impede Cbl release from lysosomes
as these conditions are all associated with impaired lysosome
function that also often includes loss of the proton gradient and
lysosomal membrane damage [13–15].
In the present study, we utilize both fibroblast and neuronal
cell lines to address fundamental questions related to lysosomal
Cbl transport. Firstly, we assess whether a lysosomal proteolysis
inhibitor, that does not operate through neutralizing lysosomal
pH, could also lead to a trapping of Cbl in the lysosome; and
secondly, we investigate whether lysosomal Cbl trapping induced
by proteolysis inhibitors could indeed have an effect on MMCM




Chloroquine (Cat no. C6628), leupeptin (N-acetyl-L-leucyl-
L-leucyl-L-argininal, Cat no. L2884), TCA (Cat no. 9159),
penicillin/streptomycin (Cat no. P4333), and HS (human serum,
Cat no. H4522) were purchased from Sigma. [57Co]cyanoCbl
(10 μCi/ml, Cat no. 06B-430002) and [14C] propionate (0.1
mCi/ml, Cat no. 11221750), were from, MP Biomedicals.
DMEM (Dulbecco’s modified Eagle’s medium, Cat no.
12800-017) and 200 mM L-glutamine (Cat no. 25030081) were
purchased from Life Technologies. FCS (Cat no. SFBS) was
from Interpath. OptiPrep (cell separation media as a 60 %
solution of iodixanol − 5,5′ − [(2-hydroxy-1,3-propanediyl)-
bis(acetylamino)] bis [N,N′-bis(2,3-dihydroxypropyl-2,4,6-
triiodo-1,3-benzenecarboxamide)) was purchased in a lysosome
enrichment kit (Cat no. 89839) from Pierce. All other general
laboratory reagents were of the highest quality available and
obtained through the standard commercial suppliers.
Cell culture
Experiments were performed using human neuroblastoma
cells (SH-SY5Y, ATCC #CRL-2266) and human fibrosarcoma
cells (HT1080, ATCC #CCL-121) obtained from the Amer-
ican Type Culture Collection (ATCC). Cells were cultured in
DMEM supplemented with 10 % (w/v) FCS, 100 μg/ml penicil-
lin/streptomycin, and 2 mM L-glutamine, at 37 ◦C in a humid-
ified atmosphere containing 5 % (v/v) CO2. Cells were grown
in 175 cm2 plastic flasks and metabolically labelled in the pres-
ence of 10 % HS for 48 h with [57Co]cyanoCbl (0.025 μCi/ml;
Cat. no. 06B-430002, MP Biomedicals) as described previously
[16]. Chloroquine (25 μM) or leupeptin (40 μM) were also added
during the final 48 h to increase lysosomal pH/inhibit lysosomal
proteolysis where indicated.
Cell homogenization and fractionation
Cell pellets were prepared using a lysosome enrichment kit
(Pierce, Cat no. 89839) and transferred to a ball-bearing cell ho-
mogenizer (Isobiotec) and homogenized on ice as described in de-
tail [16]. In brief, nuclei and membranous debris were discarded
and the organelle suspension (includes lysosomes, mitochondria
and cytosol) was collected and layered onto a discontinuous Opti-
Prep density gradient. The samples were centrifuged at 145 000 g
for 4 h at 4 ◦C using a Sorvall MTX 150 ultracentrifuge and a Sor-
vall S50ST swinging bucket rotor (Thermo Scientific). After cent-
rifugation, ten fractions were carefully withdrawn from the top
of the gradients and the organelles separated from the cytosol via
a final centrifugation at 20 000 g for 30 min at 4 ◦C as described
previously [16]. Both the organelle and cytosolic components
of each of the ten fractions were assessed for [57Co]Cbl radio-
activity, using a Wallace Gamma Counter (PerkinElmer) and for
organelle/cytosolic markers as briefly described. For the organ-
elle fractions, radioactivity in LAMP2- and VDAC1 (voltage-
dependent anion channel 1)-positive fractions was assigned as
lysosomal and mitochondrial, respectively.
In conditions where neuronal proteolysis was inhibited by
leupeptin, the density of lysosomes in two of the eight LAMP2-
positive fractions (i.e. fractions 7 and 8) became so similar to
the mitochondria that it was not possible to completely separate
them. In this case, the cpm (counts per minute) values in those
two fractions were estimated based on the LAMP2 optical dens-
ity and comparison with the closest ‘clean’ LAMP2 fractions (i.e.
fractions 5 and 6). After subtraction of the estimated lysosomal
cpm in fractions 7 and 8, the remaining cpm was assigned as mito-
chondrial. Using this method both the leupeptin and chloroquine
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(where the LAMP2/VDAC1 overlap was not pronounced) treat-
ments gave similar results for lysosomal Cbl levels.
Western blotting
Isolated cellular fractions containing lysosomes, mitochon-
dria and cytosol were probed for appropriate organelle mark-
ers by Western blotting; lysosome, LAMP2 (lysosomal-
associated membrane protein 2, Southern Biotech); mito-
chondria, VDAC1(Abcam); cytosol, β-actin (Sigma) and MS
(Abnova). Briefly, samples separated on SDS/12 % PAGE gels
(Mini-Protean II system (Bio-Rad) at 150 V for 70 min followed
by transfer at 100 V for 30 min onto 0.45 μm nitrocellulose
membranes using a Mini-Trans-Blot Electrophoretic Transfer
cell (Bio-Rad). The membranes were blocked in 5 % (w/v) non-
fat dried skimmed milk powder in PBS) for 1 h at 22 ◦C and
then probed with LAMP2 mouse monoclonal antibody (1:4000),
VDAC1 rabbit polyclonal antibody (1:4000) or MS goat poly-
clonal antibody (1:300) at 4 ◦C for 16 h, followed by incubation
with the appropriate horseradish-peroxidase-conjugated rabbit
anti-mouse (1:4000, Dako), goat anti-rabbit (1:4000, Dako) and
rabbit anti-goat (1:4000, Dako) IgG antibodies for 1 h at 22 ◦C.
Blots were rinsed in PBS and proteins were detected using en-
hanced ECL (Amersham Biosciences). The membranes were ex-
posed to ECL Hyperfilm (Amersham Biosciences), developed,
scanned and signal intensity was quantified as integrated optical
density using NIH Image software.
Mm-CoA mutase activity [14C] propionic acid
incorporation
As an indirect measure of MMCM activity, the incorporation of
[14C] propionic acid into TCA-precipitated macromolecules such
as proteins was evaluated [4,5]. Cells were grown to ∼80 % con-
fluence in 6-well plates under standard culture conditions or in
the presence of either chloroquine (25 μm) or leupeptin (40 μm)
for 48 h. The cells were then rinsed with PBS and incubated with
[14C] propionate (1 μCi/ml) in Puck’s saline containing 15 %
(v/v) FCS and 5 mM glucose for 8 h at 37 ◦C. The cells were
then rinsed with PBS and incubated with 5 % (w/v) TCA for
10 min at 4 ◦C. The cells were collected with a cell scraper and
centrifuged at 6000 g for 5 min at 4 ◦C. Finally, the supernatants
were removed and the pellets were dissolved with 1 M NaOH.
The amount of [14C] propionate in the cell pellets were measured
using a Tri-Carb Liquid Scintillation Counter (PerkinElmer). Pro-
tein concentrations in the cell pellets were determined using the
BCA (bicinchoninic acid) assay.
Data analysis
Quantitative data are presented as mean +− S.E. of three inde-
pendent experiments unless stated otherwise. Statistical differ-
ences were assessed using the t test where P < 0.05 was con-
sidered significant. Pearson’s correlation analysis was conducted
to assess the potential associations between changes in relative
mitochondrial [57Co]Cbl levels and [14C] propionate incorpora-
tion into TCA-precipitated cell pellets. Statistical analyses were
performed using SPSS Statistics v19.0.0 (IBM).
RESULTS
Chloroquine and leupeptin impair subcellular Cbl
transport in HT1080 fibroblasts
Consistent with previously established methods [16], the separa-
tion of fibroblast organelles through an OptiPrep gradient yielded
pure lysosomes (LAMP2 positive fractions no. 1–5) and mito-
chondria (VDAC1 positive fractions no. 7–9) as demonstrated by
Western blotting (Figure 1A). The organelle fractions contained
only trace amounts of β-actin and were also free of detectable
MS, whereas clear signals for both β-actin and MS were detected
in the cytosolic fractions.
Previous data indicated that treatment of fibroblasts with
chloroquine (25 μM for 21 h) resulted in a dramatic increase
in the amount of [57Co]Cbl that eluted from a Sephacryl S-200
column in the same position as TC, consistent with a retention of
Cbl in lysosomes [6]. In the current study, we directly evaluated
the amount of [57Co]Cbl in isolated lysosome fractions. Under
the standard culture conditions, fibroblast lysosomes contained
5.7 % of cellular [57Co]Cbl and this was increased 3.1-fold to
17.6 % with chloroquine treatment (Figure 1). This retention
of [57Co]Cbl in the lysosome was associated with a significant
63 % drop (from 14.3 to 5.2 % of the total cellular levels) in
mitochondrial [57Co]Cbl and a trend (P = 0.07) for a 4 % drop
(from 80.1 to 77.1 % of the total cellular levels) in cytosolic
[57Co]Cbl (Figure 1).
Since chloroquine inhibits lysosomal proteolysis and can the-
oretically also modulate the transition of lysosomal Cbl to the
base-off state (as explained above), we also conducted the sim-
ilar experiments using another proteolysis inhibitor that does not
alter lysosomal pH. We selected the broad specificity competit-
ive transition state inhibitor leupeptin (inhibits cysteine, serine
and threonine peptidases) for this purpose. Similar to the results
using choroquine, leupeptin treatment also led to a significant 3.9-
fold increase in lysosomal [57Co]Cbl that was associated with a
reduction in both mitochondrial and cytosolic [57Co]Cbl levels
(reduced by 44 and 13 %, respectively; Figure 1).
Interestingly, both chloroquine and leupeptin treatments were
associated with the appearance of LAMP2 through a broader
range of density fractions isolated from the gradient (compare
Figure 1A with Figures 1B and 1C). This may result from both
an expansion of the lysosomal compartment and an increase in
the size and density of a subpopulation of lysosomes; both of
which would be predicted to occur as intralysosomal substrates
accumulate [17,18].
Chloroquine and leupeptin impair subcellular Cbl
transport in SH-SY5Y neurons
Previous data suggest that age-related lysosomal dysfunction is a
particular problem in post-mitotic cells such as neurons [14,19].
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Figure 1 Protease inhibitors increase [57Co]Cbl retention in fibroblast lysosomes
Approximately 16×106 HT1080 fibroblasts were metabolically labelled with [57Co]Cbl for 48 h. The radiolabelled cells were
disrupted using a ball-bearing homogenizer and the lysosomal, mitochondrial and cytosolic fractions were separated using
an OptiPrep gradient. Intracellular marker proteins LAMP2 (lysosomal), VDAC1 (mitochondrial), β -actin and MS (cytosolic)
were then probed by Western blotting in all fractions. Cells were assessed under the standard ‘Control’ culture conditions
(A) and after the treatment with 25 μM chloroquine for 48 h (B), 40 μM leupeptin for 48 h (C). The proportional distribution
of [57Co]Cbl was assessed using a gamma counter and expressed as a percentage of radioactivity in each fraction (D).
Positions of molecular mass markers (kDa) are shown on the blots. Fractions are labelled 1–10, from lightest (top of
gradient) to heaviest (bottom of gradient). Cyto, cytosol. (A–C) Data are representatives of three independent experiments.
(D) Data are means with S.E. represented by the error bars (n = 3 experiments for each condition).*P < 0.05, **P < 0.01,
#P = 0.07.
We therefore conducted further experiments to assess the impact
that lysosomal impairments induced by either chloroquine or leu-
peptin may have on Cbl distribution in SH-SY5Y neurons. The
treatment of neurons with either chloroquine or leupeptin dra-
matically increased the lysosomal [57Co]Cbl levels by ∼10-fold
in SH-SY5Y neurons and this was associated with a significant
∼50 % reduction in the cytosolic [57Co]Cbl levels (Figure 2).
Mitochondrial [57Co]Cbl levels were also significantly decreased
after either chloroquine or leupeptin treatment (by 48 and 16 %,
respectively; Figure 2).
In comparing the experiments conducted using fibroblasts and
neurons, there were striking differences in the degree of lyso-
somal accumulation of [57Co]Cbl and cytosolic depletion of
[57Co]Cbl, with both parameters being much more severe in
the neuronal cell line. In addition, associated with the more
pronounced lysosomal [57Co]Cbl accumulation, the change in
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Figure 2 Protease inhibitors increase [57Co]Cbl retention in neuronal lysosomes
Approximately 16×106 SH-SY5Y neurons were metabolically labelled with [57Co]Cbl for 48 h. The radiolabelled cells were
disrupted using a ball-bearing homogenizer and the lysosomal, mitochondrial and cytosolic fractions were separated using
an OptiPrep gradient. Intracellular marker proteins LAMP2 (lysosomal), VDAC1 (mitochondrial), β -actin and MS (cytosolic)
were then probed by Western blotting in all fractions. Cells were assessed under standard ‘Control’ culture conditions (A)
and after the treatment with 25 μM chloroquine for 48 h (B), 40 μM leupeptin for 48 h (C). The proportional distribution of
[57Co]Cbl was assessed using a gamma counter and expressed as a percentage of radioactivity in each fraction (D). Posi-
tions of molecular mass markers (kDa) are shown on the blots. Fractions are labelled 1–10, from lightest (top of gradient)
to heaviest (bottom of gradient). Cyto, cytosol. (A–C) Data are representatives of three independent experiments. (D) Data
are means with S.E. represented by the error bars (n = 3 experiments for each condition). **P < 0.01, ***P < 0.0001.
LAMP2 distribution through the OptiPrep density gradient was
also more pronounced in the SH-SY5Yneurons (compare Fig-
ures 1B and 1C with 2B and 2C); possibly reflecting a more ex-
tensive enlargement of the lysosomal compartment and a greater
increase in average lysosome size and density distribution. It was
also clear that there were differences in the extent to which mito-
chondrial [57Co]Cbl levels were modulated by chloroquine and
leupeptin treatments in the different cell types and this did not
necessarily follow the changes in lysosomal [57Co]Cbl retention;
for example, leupeptin treatment of SH-SY5Y neurons resulted
in an approximate 10-fold increase in lysosomal [57Co]Cbl and
an approximate 50 % decrease in cytosolic [57Co]Cbl, whereas
in the same experimental conditions the mitochondrial [57Co]Cbl
levels were reduced by only 16 % (Figure 2D).
Lysosomal protease inhibition results in reduced
mitochondrial [57Co]Cbl that is correlated with
impaired MMCM activity
In order to assess whether the variation in mitochondrial
[57Co]Cbl levels associated with chloroquine or leupeptin treat-
ment was associated with changes in MMCM activity, we used
an established method that is based on the incorporation of [14C]
propionate into TCA-precipitated proteins/macromolecules [4].
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Figure 3 Protease inhibitors reduce cellular [14C] propionate incorporation
HT1080 fibroblasts and SH-SY5Y neurons were grown to ∼80 % confluence in 6-well plates and metabolically labelled
with [14C] propionate under the standard culture conditions or in the presence of either chloroquine (25 μm) or leupeptin
(40 μm) for 48 h. The cells were then subjected to 5 % TCA and [14C] propionate in the cell pellets determined and
expressed as a percentage of the control conditions (A). Pearson’s correlation analysis was conducted to assess potential
associations between changes in relative mitochondrial [57Co]Cbl levels (derived from the experiments shown in Figures 1
and 2) and [14C] propionate incorporation into TCA-precipitated cell pellets (B).*P < 0.05, #P = 0.07.
Chloroquine treatment resulted in a significant inhibition of [14C]
propionate incorporation into TCA-precipitated pellets in both
fibroblasts and neurons (25.5 and 15.7 % reduction, respectively;
Figure 3A). Similarly, leupeptin treatment significantly reduced
[14C] propionate incorporation in fibroblasts (by 24.6 %) and
there was a trend for reduced [14C] propionate incorporation
in neurons (5.7 %, P = 0.07; Figure 3A). When the variation in
mitochondrial [57Co]Cbl levels associated with chloroquine or
leupeptin treatment was compared with the relative [14C] pro-
pionate incorporation values, a significant positive correlation
(R2 = 0.88, P = 0.003) was detected (Figure 3B). This suggests
that lysosomal entrapment of Cbl may have down-stream con-
sequences on cellular physiology.
DISCUSSION
In the present work, we have shown that inhibition of lyso-
somal proteolysis using both pH-dependent and -independent ap-
proaches leads to lysosomal Cbl accumulation. Western blotting
for LAMP2 in OptiPrep gradient fractions suggested that such
lysosomal Cbl ‘trapping’ is also associated with an expansion of
the lysosomal compartment and an increase in a subpopulation
of lysosomes with increased size and/or density. Moreover, lyso-
somal Cbl trapping was correlated with decreased incorporation
of [14C] propionate into cellular proteins/macromolecules; which
is a physiological marker of MMCM activity.
Consistent with our previous data [16], only ∼6 % of cellular
[57Co]Cbl resides in the lysosome. This was not unexpected as
the major sites of Cbl utilization in humans are MS and MMCM,
enzymes that are located in the cytosol and mitochondria, respect-
ively. The relatively low level of lysosomal Cbl probably reflects
the transient nature of this pool as it is released from the TC–
Cbl complex and transported from the lysosome via LMBD1 and
ABCD4 [5,7]. Although previous data derived from the cultured
human fibroblasts suggest that under control conditions 37.5 % of
[57Co]Cbl resides in lysosomes (fractions from a sucrose gradi-
ent of d 1.036 to 1.096 g/ml that contained 90.3 % of cellular
acid phosphatase and 89.6 % N-acetly-β-glucosaminidase activ-
ity) [6], these earlier studies did not report on possible contam-
ination of lysosomal fractions with cytosol/MS and that may
account for the higher values than we report herein. In these
earlier studies, patients with a defect in lysosomal release of Cbl
were found to accumulate 92.8 % of [57Co]Cbl in lysosomes,
which is a more pronounced lysosomal trapping of Cbl than we
detected with the short-term treatment of cells with protease in-
hibitors. Nevertheless, depending on the cell type examined, we
found that increasing the amount of [57Co]Cbl in lysosomes from
∼6 % up to ∼20 − 50 % was sufficient to impair Cbl-dependent
utilization of [14C] propionic acid. Based on these data we specu-
late that in pathophysiological conditions, that involve lysosomal
dysfunction, a similar impairment of Cbl transport may also oc-
cur and that could contribute to down-stream changes in Cbl
utilization. Examples of conditions that are associated with lyso-
somal dysfunction (several of which are associated with loss
of the proton gradient across the lysosomal membrane) include
age-related lipofuscin accumulation [13,19], lysosomal storage
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diseases [20–22], Alzheimer’s disease [23,24] and Parkinson’s
disease [25–27].
Our results do not allow us to determine whether lysosomal
trapping induced by either chloroquine or leupeptin is due to an
expansion of the lysosomal compartment or an increase in the
amount of Cbl retained in each lysosome. When the [57Co]Cbl
cpm values were compared with LAMP2 signal in the pure lyso-
some fractions, we generally observed a close correlation (H.
Zhao and B. Garner, unpublished data); however, in conditions
where we detected a 10-fold increase in lysosomal [57Co]Cbl, we
did not observe a change in LAMP2 of the same magnitude. For
example, a semi-quantitative comparison of the LAMP2 West-
ern blots (H. Zhao and B. Garner, unpublished data) suggested
chloroquine treatment increased LAMP2 levels ∼2-fold, whereas
the lysosomal [57Co]Cbl level was increased ∼10-fold (Figure 2).
Interestingly, the recent studies suggest that lysosomal protease
inhibitors (including chloroquine) have a dual effect on auto-
phagy as they initiate early autophagic processes while suppress-
ing autophagic degradation [28]. This is predicted to result in an
expansion of the lysosomal compartment that may be mechanist-
ically related to our current observations. We therefore conclude
that Cbl trapping in the lysosome that is induced by protease
inhibition is most probably because of a combination of both
an expansion of the lysosomal compartment and an increase in
lysosomal Cbl concentration.
Another unresolved question that arises from the current study
concerns the marked differences in lysosomal [57Co]Cbl trap-
ping in fibroblasts as compared with neurons and the associated
changes in cytosolic versus mitochondrial [57Co]Cbl distribu-
tion. In the SH-SY5Y neurons, we observed a very significant
drop in cytosolic [57Co]Cbl when lysosomal proteolysis inhib-
itors were present. If the half-life of MS was shorter than the
half-life of MMCM, then one might predict a more rapid drop
in the [57Co]Cbl cytosolic pool; however, the predicted half-lives
of these enzymes [29,30] are 30 and 5.5 h, respectively. There-
fore the differences in enzyme half-life are unlikely to account
for the relative sensitivity of these pools. We are unaware of de-
tailed studies on MS and MMCM turnover in neurons and the
impact that Cbl deficiency may have on enzyme half-life but,
based on the fact that Cbl deficiency includes a neurological
phenotype [31–33], these issues appear to be worthy of future
study.
In conclusion, the present study shows that inhibition of lyso-
somal proteolysis leads to lysosomal Cbl accumulation in fibro-
blasts and neurons. This lysosomal Cbl trapping appears to be
associated with an expansion of the lysosomal compartment
and an increase in a subpopulation of lysosomes with increased
size and/or density. This is associated with decreased mitochon-
drial Cbl and an inhibition of MMCM activity as indicated by
decreased incorporation of [14C] propionate into cellular pro-
teins/macromolecules.
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